S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice

NeuroPace Stock Price, News & Analysis (NASDAQ:NPCE)

$8.31
+0.18 (+2.21%)
(As of 12/5/2023 ET)
Compare
Today's Range
$7.69
$8.41
50-Day Range
$5.90
$9.73
52-Week Range
$1.22
$9.73
Volume
63,265 shs
Average Volume
45,133 shs
Market Capitalization
$218.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

NeuroPace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
15.5% Upside
$9.60 Price Target
Short Interest
Healthy
1.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.15mentions of NeuroPace in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$191,658 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.38) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

345th out of 948 stocks

Surgical & Medical Instruments Industry

36th out of 82 stocks


NPCE stock logo

About NeuroPace Stock (NASDAQ:NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Stock Price History

NPCE Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
NeuroPace 10% Owner Trades $75K In Company Stock
OrbiMed Advisors LLC Reduces Stake in NeuroPace Inc
Morgan Stanley Upgrades NeuroPace (NPCE)
NeuroPace, Inc.: NeuroPace Announces CEO Transition
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$11.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-47,080,000.00
Pretax Margin
-62.96%

Debt

Sales & Book Value

Annual Sales
$60.20 million
Book Value
$1.40 per share

Miscellaneous

Free Float
19,056,000
Market Cap
$218.42 million
Optionable
Not Optionable
Beta
2.13
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














NPCE Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price target for 2024?

5 brokerages have issued 12 month price objectives for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $11.00. On average, they expect the company's share price to reach $9.60 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2023?

NeuroPace's stock was trading at $1.49 at the start of the year. Since then, NPCE stock has increased by 457.7% and is now trading at $8.31.
View the best growth stocks for 2023 here
.

Are investors shorting NeuroPace?

NeuroPace saw a decrease in short interest in November. As of November 15th, there was short interest totaling 151,000 shares, a decrease of 61.8% from the October 31st total of 395,600 shares. Based on an average daily trading volume, of 69,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.4% of the company's shares are sold short.
View NeuroPace's Short Interest
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our NPCE earnings forecast
.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.11. The firm earned $16.43 million during the quarter, compared to analyst estimates of $14.23 million. NeuroPace had a negative net margin of 62.96% and a negative trailing twelve-month return on equity of 151.83%.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

Who are NeuroPace's major shareholders?

NeuroPace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (9.13%), FMR LLC (2.69%), Kent Lake Capital LLC (2.19%), EAM Investors LLC (0.54%), Barclays PLC (0.04%) and Citigroup Inc. (0.01%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley, Ltd Kck and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NPCE) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -